Prelude Therapeutics, Inc. PRLD 深 沪
已收盘 08-21 16:00:00 美东时间
6.63
+0.130
+2.00%
华盛通- 最 高6.8162
- 今 开6.56
- 成交量 51.92万股
- 最 低 6.40
- 昨 收 6.50
- 总市值 5.29亿
- 52周最高 6.8162
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 0.9807
- 委 比 -31.93%
- 总股本 7980.35万
- 历史最高 95.375
- 量 比 0.67
- 振 幅 6.40%
- 历史最低 0.6101
- 每 手 1
- 风险率 1.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 比特币突破7.7万美元大关！加密概念股普升，嘉楠科技劲升16%，MARA升逾15%，比特数字升近14%
政策利好集中释放！比特币突破7.5万美元大关，加密概念股普升，嘉楠科技劲升16%，MARA升逾15%，比特数字升近14%；ANDG升近12%，发售1.8亿美元股票>>
08-21 16:01
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-12 03:18
Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 65.85 percent increase over losses of $(0.41) per share from the same period last year. The company reported $5.704 million in sales this qu...
08-11 19:23
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics reported Q2 2026 financial results with $155 million in cash and plans to initiate a Phase 1 study for its KAT6A degrader PRT13722 in HR+ breast cancer by Q4 2026. The company also continues enrollment in its Phase 1 study for PRT12396, a JAK2V617F inhibitor for PV and MF. Financials show a net loss of $13.9 million, down from $31.2 million in 2025, with R&D and G&A expenses decreasing. The company expects its cash runway to ...
08-11 11:00
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE:SHW) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 guidance. Sherwin-Williams reported quarterly earnings of ...
07-28 22:05
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler joins the Audit Committee, while Cox becomes Chair of the Nominating and Corporate Governance Committee. Both bring extensive experience in biotechnology leadership. Babler previously led Alumis Inc., Principia Biopharma Inc., and Talima Therapeutics, Inc., while Cox served as CEO of Foundation...
06-24 11:00
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Dave and Buster’s Entertainment, Inc (NASDAQ:PLAY) fell sharply in pre-market trading as the company reported downbeat earnings for the first quarter. The company posted quarterly earnings of ...
06-16 20:05
Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.25) by 48 percent. This is a 69.05 percent increase over losses of $(0.42) per share from
05-12 19:46
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
